Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tiemo-Joerg Bandel is active.

Publication


Featured researches published by Tiemo-Joerg Bandel.


European Respiratory Journal | 2018

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

Anthony De Soyza; Timothy R. Aksamit; Tiemo-Joerg Bandel; Margarita Criollo; J. Stuart Elborn; Elisabeth Operschall; Eva Polverino; Katrin Roth; Kevin L. Winthrop; Robert Wilson

We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and pre-defined bacteria in sputum. In this phase III, double-blind, placebo-controlled trial, patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in two treatment regimens consisting of on/off treatment cycles of 14 or 28 days for 48 weeks. The primary end-points were time to first exacerbation and frequency of exacerbations. A total of 416 patients were randomised to the 14-day on/off regimen (ciprofloxacin DPI (n=137) and placebo (n=68)) or the 28-day on/off regimen (ciprofloxacin DPI (n=141) and placebo (n=70)). Ciprofloxacin DPI 14 days on/off significantly prolonged time to first exacerbation versus pooled placebo (median time >336 versus 186 days; hazard ratio 0.53, 97.5% CI 0.36–0.80; p=0.0005) and reduced the frequency of exacerbations compared with matching placebo by 39% (mean number of exacerbations 0.6 versus 1.0; incidence rate ratio 0.61, 97.5% CI 0.40–0.91; p=0.0061). Outcomes for ciprofloxacin DPI 28 days on/off were not statistically significantly different from placebo. The safety profile of ciprofloxacin DPI was favourable. Ciprofloxacin DPI was well tolerated and has the potential to be an effective treatment option in non-cystic fibrosis bronchiectasis. In RESPIRE 1, 14-day on/off cycles of ciprofloxacin dry powder for inhalation reduced bronchiectasis exacerbations http://ow.ly/po4s30gNfl0


European Urology | 2004

The Efficacy and Safety of Flexible-Dose Vardenafil (Levitra®) in a Broad Population of European Men

Dimitrios Hatzichristou; Francesco Montorsi; Jacques Buvat; Nicole Laferriere; Tiemo-Joerg Bandel; Hartmut Porst


Archive | 2002

Use of 2-alkoxyphenol-substituted imidazotriazinones

Ulrich Niewöhner; Maria Theresia Niewohner; Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth


Archive | 2001

Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain

Ulrich Niewoehner; Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth


Archive | 2002

Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen

Tiemo-Joerg Bandel; Wolfgang Barth; Erwin Bischoff; Helmut Haning; Ulrich Niewoehner; Afssaneh Rahbar


Archive | 2002

Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von herzinsuffizienz

Ulrich Niewöhner; Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth


Archive | 2002

Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes

Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth; Ulrich Niewöhner


Archive | 2002

Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von herzinsuffizienz Use of 2-alkoxyphenyl-substituted imidazotriazinones to treat heart failure

Ulrich Niewoehner; Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth


Archive | 2002

Utilisation d'imidazotriazinones 2-alkoxyphenyl substituees pour le traitement de l'insuffisance cardiaque

Ulrich Niewöhner; Erwin Bischoff; Helmut Haning; Afssaneh Rahbar; Tiemo-Joerg Bandel; Wolfgang Barth


Archive | 2002

Imidazotriazinonas new use of 2- (2-ethoxy-5- (4-methylpiperazin-1-sulfonyl) -phenyl) -5-methyl-7-propyl-3H-imidazo (5,1-f) (1, 2,4) triazin-4-one.

Tiemo-Joerg Bandel; Wolfgang Barth; Erwin Bischoff; Helmut Haning; Ulrich Niewöhner; Afssaneh Rahbar; Der Staay Franz-Josef Van

Collaboration


Dive into the Tiemo-Joerg Bandel's collaboration.

Researchain Logo
Decentralizing Knowledge